APA

Gueorguieva I., Cleverly A. L., Stauber A., Sada Pillay N., Rodon J. A., Miles C. P., Yingling J. M. & Lahn M. M. (20150207). Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. : British journal of clinical pharmacology.

Chicago

Gueorguieva Ivelina, Cleverly Ann L, Stauber Anja, Sada Pillay N, Rodon Jordi A, Miles Colin P, Yingling Jonathan M and Lahn Michael M. 20150207. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. : British journal of clinical pharmacology.

Harvard

Gueorguieva I., Cleverly A. L., Stauber A., Sada Pillay N., Rodon J. A., Miles C. P., Yingling J. M. and Lahn M. M. (20150207). Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. : British journal of clinical pharmacology.

MLA

Gueorguieva Ivelina, Cleverly Ann L, Stauber Anja, Sada Pillay N, Rodon Jordi A, Miles Colin P, Yingling Jonathan M and Lahn Michael M. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. : British journal of clinical pharmacology. 20150207.